A Phase I/IIa Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer
Latest Information Update: 04 Nov 2024
At a glance
- Drugs Imaging agents (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Yunhe Pharmaceutical (Tianjin)
Most Recent Events
- 30 Oct 2024 Status changed from recruiting to completed.
- 05 Jul 2024 New trial record